Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial - Concepedia

Concepedia

Publication | Open Access

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

DOI Full Paper Access

16

Citations

17

References

2024

Year

Chijioke Bennett, Wayne Woo, Mark Bloch, King Cheung, Paul Griffin, Rahul Mohan, Sachin Kumar Deshmukh, Mark Arya, Oscar Cumming, A. Munro Neville,

The Lancet Infectious Diseases

References

	Year	Citations

Page 1